ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNo targeted therapy combinations have achieved regulatory approval for the treatment of biomarker-positive resistance in non-small cell lung cancer (NSCLC). Given the widespread availability of next-generation sequencing (NGS) to detect resistance, we reviewed the real-world experience of using off-label targeted therapy combinations to treat advanced NSCLC at our academic safety-net hospital.
methodsPharmacy records from the Hematology/Oncology Department at Boston Medical Center during the years 2017 to 2024 were reviewed. One hundred eleven patients received oral, targeted therapy during this time. Our study focused on those patients who received an off-label combination of targeted therapies for advanced NSCLC. We reviewed their demographics, treatment history, molecular data, and published evidence to support the combination.
resultsEight patients were treated with nine combination regimens. The median age was 69 years (age 29-89 years). Six patients had EGFR exon 19 deletions and two had EML4-ALK fusions. The nine combination regimens included addition of a MET inhibitor (n = 3), a RET inhibitor (n = 2), a MEK inhibitor (n = 2), an ALK inhibitor (n = 1), and an EGFR antibody (n = 1). The median duration of treatment was 7 months (range: 1-35 months), and was longest for alectinib and capmatinib (15 months ongoing and 25 months, ongoing) and gefitinib and selpercatinib (35 months, ongoing). Available supporting evidence included retrospective cohort studies (n = 5), published case reports/series (n = 2), and a prospective cohort study (n = 1).
conclusionOff-label combination therapy to treat targeted therapy resistance in advanced NSCLC is feasible in routine clinical practice. Additional real-world evidence is needed to clarify best practices with this emerging approach.
Indexed as
Identifiers
41484568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.